Shares of Cambrex (CBM) are down roughly 5% since reporting softer Q1 results in early May, William Blair analyst John Kreger tells investors in a research note. The analyst expects a stronger Q2 relative to Q1, which he believes should keep the full-year outlook on track. Further, his sum-of-the-parts analysis indicates that Cambrex is reasonably valued even if the Gilead (GILD) business continues to decline quickly. Kreger calculates Cambrex's base business, excluding hepatitis C revenues from Gilead, is currently valued at 11.3 times his 2019 EBITDA estimate. This is a "meaningful" discount to both its public and private peers, which have garnered deal multiples in the 13-14 times range, the analyst points out. He believes the stock's risk/reward profile is "compelling for investors willing to be patient." Kreger reiterates an Outperform rating on Cambrex.